NCT00730145

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.

Detailed description

Assess the elimination of PD-0332334 from the blood with hemodialysis

Conditions

• Renal Dialysis
• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	PD-0332334	A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2008-08-08
• Last updated: 2010-02-17

Locations

1 site across 1 country: United States